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ABSTRACT
Fungi are responsible for around 20% of
microbiologically documented infections in
intensive care units (ICU). In the last decade,
the incidence of invasive fungal infections (IFI),
including candidemia, has increased steadily
because of increased numbers of both
immunocompromised and ICU patients. To
improve the outcomes of patients with IFI,
intensivists need to be aware of the inherent
challenges. This narrative review summarizes
the features of routinely used treatments direc-
ted against IFI in non-neutropenic ICU patients,
which include three classes of antifungals:
polyenes, azoles, and echinocandins. ICU
patients’ pathophysiological changes are
responsible for deep changes in the pharma-
cokinetics of antifungals. Moreover, drug inter-
actions affect the response to antifungal
treatments. Consequently, appropriate anti-
fungal dosage is a challenge under these special
conditions. Dosages should be based on renal
and liver function, and serum concentrations
should be monitored. This review summarizes
recent guidelines, focusing on bedside
management.
Keywords: Candidiasis; Intensive care patients;
Invasive aspergillosis; Invasive fungi infection;
Pharmacokinetics; Practical guidelines
INTRODUCTION
Fungi are responsible for approximately 20% of
microbiologically documented intensive care
unit (ICU) infections [1]. In the last decade, the
incidence of invasive fungal infections (IFI),
including candidemia, has steadily increased as
a result of the increasing numbers of both
immunocompromised and critically ill patients
[2–6].
Candida spp. are the third leading cause of
infections in the ICU, accounting for 90% of
fungal infections [1]. Invasive candidiasis (IC)
includes bloodstream and deep infections
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caused by the Candida species. Studies have
shown a cumulative incidence of 7.07 episodes
of IC per 1000 ICU admissions [7]. Of note, over
recent decades the incidence of Candida albicans
infections has decreased with a relative increase
in non-albicans Candida infections, including
the fast emergence of Candida auris [8–10]. In
ICU patients, IC became a challenge with a
mortality rate approaching 40% [11]. Although
attributable mortality is difficult to establish,
candidemia has been identified as an indepen-
dent predictor of mortality after controlling for
confounders [12]. Delay in initiating adequate
antifungal treatment is associated with
increased mortality. Remarkably, antifungal
treatment recommendations remain largely
based on randomized clinical trials that were
not restricted to ICU patients.
Invasive aspergillosis (IA) is an opportunistic
infection that occurs mainly in patients with
prolonged periods of neutropenia with or
without hematological malignancies, patients
who underwent allogeneic stem cell transplan-
tation or solid organ transplantation, and
patients with HIV/AIDS. In recent years, how-
ever, IA has increasingly been recognized as an
emerging disease in non-neutropenic individu-
als, including patients with chronic obstructive
pulmonary disease and other chronic lung or
connective tissue diseases requiring corticos-
teroid therapy, decompensated liver cirrhosis or
acute liver failure, solid cancer, chronic renal
failure with replacement therapy, diabetes,
severe influenza, and even ICU patients without
any risk factors apart from a prolonged stay [13].
The incidence of Aspergillus spp. infections
ranges from 0.3% to 6.9% in ICU patients [14].
Prompt administration of an effective treatment
for IA is critical to reduce the mortality rate,
which ranges from 60% to 90% [14]. Inten-
sivists need to be aware of the specific risk fac-
tors for IFI as well as the diagnostic and
therapeutic challenges to improve outcome.
The aim of this narrative review was to
summarize clinically relevant knowledge on the
currently used antifungals, focusing on non-
neutropenic ICU patients. These patients are
indeed at risk of IFI because of pathophysio-
logical changes that influence drug pharma-
cokinetics (PK).
This article is based on previously conducted
studies and does not contain any studies with
human participants or animals performed by
any of the authors.
ANTIFUNGAL DRUG CLASSES
Since the 1980s there has been an increasing but
limited discovery of antifungal agents [15, 16].
The three principal classes of antifungal agents
are polyenes, azoles, and echinocandins. Details
on pharmacokinetics are provided in Table 1.
Table 2 summarizes the features of antifungals
in patients with renal or liver failure.
Polyenes
Polyenes (amphotericin B and nystatin) act in
the fungal membrane by binding to ergosterol
and causing disruption of the membrane struc-
ture promoting extravasation of intracellular
constituents and, consequently, cell death
(Fig. 1) [17]. They have a broad spectrum of
action, fungicidal activity, and an activity
against most Candida, most Aspergillus, and
Mucorales species. However, many Candida lusi-
taniae and Aspergillus terreus strains are resistant
to amphotericin B (Tables 3, 4).
The standard amphotericin B formulation is
associated with renal toxicity, caused by the
vasoconstriction of the afferent arteriole,
resulting in reduced renal blood flow and
glomerular filtration rate combined with tubu-
lar injury, causing loss of potassium, magne-
sium bicarbonates, and amino acids. To reduce
renal injury, liposomal amphotericin B allows
lower absorption of amphotericin B by the
reticuloendothelial system, resulting in a longer
stay in the bloodstream.
Amphotericin B is contraindicated in
patients with renal failure. Liposomal ampho-
tericin B and amphotericin B lipid complex are
less nephrotoxic than conventional ampho-
tericin B, allowing a higher dosage because their
PK are very different [20]. Since enteral absorp-
tion is negligible for all commercially available
amphotericin B formulations, they must be
administered by intravenous infusion.
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Amphotericin 95–99 0.5–2 1.7–2.8 15–27 Bile, kidney (80%)
No metabolite yet identified
0.3 mg/kg on day 1
? 5 mg per day until 1 mg/
kg





13–24 Bile, RES long-term disposition,
final elimination not yet clear,
no metabolites identified
3–4 mg/kg per day
Tinf[ 4 h recommended
Fluconazole 12 0.7 9 30 Mainly unchanged via the
kidney, tubular reabsorption
IV loading dose: 12 mg/kg
once
Maintenance dose: 6 mg/kg
per 24 h
Voriconazole 58 4.5 4.4 6 Hepatic metabolism involving
2C9, 2C19, and CYP3A4
Strong inhibitor
IV loading dose: 6 mg/kg on
day 1
Maintenance: 4 mg/kg per
12 h
Isavuconazole 98–99 6.5 2.6 80–120 Hepatic metabolism involving
UGT, CYP3A4
Moderate inhibitor
IV loading dose: 200 mg day
1 and day 2
Maintenance dose: 200 mg
per 24 h
Caspofungin 92–97 0.3–2 10 8 Independent from cytochrome
P450
IV loading dose: 70 mg
Maintenance dose 50 mg
(70 mg if body
weight[ 80 kg)
Anidulafungin 99 0.6 7 40–50 Spontaneous degradation in
plasma
Loading dose: 200 mg (Tinf
180 min)
Maintenance dose: 100 mg
(Tinf 90 min)
Micafungin 99.9 0.3 18 13–20 CYP involved 50 mg for prophylaxis,
100 mg for candidiasis,
150 mg for esophageal
candidiasis
Details and references are displayed in the text
Cmax peak level, T1/2 half-life, Cl clearance, Vd apparent volume of distribution, Tinf infusion time, RES reticuloendothelial
system, CYP cytochrome, UGT urindin diphosphate glucuronosyltransferase
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Infusion-related adverse events include
chills, rigor, fever, hypotension or hyperten-
sion, hypoxia, nausea, vomiting, and hypoka-
lemia, and affect about half of patients treated
with conventional amphotericin B. The adverse
event mechanisms are driven by activation of
proinflammatory pathways [21–23].
Table 2 Overview on pharmacokinetics of antifungals in patients with renal or liver failure
Drug Renal impairment Liver impairment Suggestions




No dose adjustment if
continuous
No dosage adjustment ICU patients: decreased plasma
levels, increased dosage?
Fluconazole Dose reduction by 50%
for GFR 11–50 ml/min
Enhanced dose if
continuous RRT
No dosage adjustment Obese critically ill: actual body
weight
ICU patient: enhanced doses
Strong inhibitor of CYP3A4 and
2C9




Mild to moderate hepatic impairment:
50% dose reduction,
TDM recommended
Strong inhibitor of CYP2C0 and
2C19
Moderate inhibitor of CYP3A4
Isavuconazole No dose adjustment Enhanced levels, no dosage reduction Moderate inhibitor of CYP3A4,
P-gp, and BRCP
Posaconazole No dose adjustment for
oral route
No dose adjustment Strong inhibitor of CYP3A4
causing drug–drug interactions
Caspofungin No dose adjustment Enhanced exposure in moderate
hepatic impairment: dosage
reduction
Dosage reduction in critically ill
patients with liver dysfunction may
cause underexposure
Anidulafungin No dose adjustment Slightly lowered concentrations but no
dosage adjustment recommended
Micafungin No dose adjustment
RRT: no dose adjustment
Slightly lowered concentrations Potential risk for liver tumors: use
only if other antifungals are not
appropriate
Details and reference are displayed in the text
RRT renal replacement therapy, SBECD sulfobutylether-b-cyclodextrin, TDM therapeutic drug monitoring, CYP cyto-
chrome, P-gp P-glycoprotein, BCRP breast cancer resistance protein, UGT urindin diphosphate glucuronosyltransferase,
GFR glomerular filtration rate
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Fig. 1 Mechanism of action of traditional antifungal
agents on cellular targets. Azoles inhibit the ergosterol
synthesis in the endoplasmic reticulum of the fungal cell.
They act by interfering with the enzyme lanosterol
14-alpha demethylase, involved in the transformation of
lanosterol into ergosterol. Polyenes act in the fungal
membrane by binding to ergosterol and causing disruption
of the membrane structure, promoting extravasation of
intracellular constituents and consequent cell death.
Echinocandins inhibit 1,3-beta-D-glucan synthase, thereby
preventing synthesis of glucan, which is present in the cell
membrane of fungi [18]
Table 3 Profile of intrinsic susceptibility and resistance of Candida species [19]
Fungi Fluconazole Voriconazole Amphotericin Echinocandin
Candida albicans S S S S
Candida 
dubliniensis
S S S S
Candida glabrata S/R S/R S S
Candida 
parapsilosis
S S S R
Candida tropicalis S S S S
Candida krusei R S S S
Candida kefyr S S S S
Uncommon 
Candida species
Candida lusitaniae S S R S
Candida auris S S S S
Candida 
guilliermondii
S S S S/R
Green, intrinsic susceptibility of the species and first line treatment recommended; red, intrinsic resistance; yellow, sus-
ceptibility to be tested
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Azoles
Azoles act by inhibiting ergosterol synthesis in
the endoplasmic reticulum of the fungal cell
(Fig. 1). They have fungistatic properties affect-
ing cell growth and proliferation. Candida krusei
and Candida glabrata strains may show resis-
tance against azoles (Table 3) [24]; however, a
large accumulation of toxic sterols can eventu-
ally lead to fungal cell death [25, 26].
Triazoles include fluconazole, itraconazole,
voriconazole, posaconazole, and isavuconazole.
The most frequent side effects induced by tria-
zoles include liver toxicity, prolonged QTc, and
emerging resistance among fungal isolates [27].
Moreover, triazoles inhibit most of the cyto-
chrome P450 enzymes (including the CYP34A),
inducing variable drug–drug interactions. This
plays a key role in metabolizing immunosup-
pressant drugs such as cyclosporine, tacrolimus,
and sirolimus [28]. Thus, co-administration of a
triazole with these immunosuppressant drugs
increases the risk of toxicity, or upon discon-
tinuation, increases the risk of rejection or graft-
versus-host disease. Close therapeutic drug
monitoring of both immunosuppressants and
triazoles is therefore indispensable.
Fluconazole
Fluconazole is available for intravenous and oral
administration with high bioavailability. It is
active on most Candida species and is usually
well tolerated. ICU patients treated with flu-
conazole should receive a loading dose (12 mg/
kg) followed by a maintenance dose (6 mg/kg)
[29]. This dosage is supported because of
impaired target site penetration in septic
patients [30]. For obese ICU patients, flucona-
zole dosage should be based on actual body
weight [31]. For patients with renal failure
(creatinine clearance 11–50 mL/min) it is nec-
essary to reduce the maintenance dose by 50%
because of delayed elimination [32]. Large
amounts of fluconazole are eliminated by renal
replacement therapy.
Voriconazole
Voriconazole has high bioavailability and is
available for intravenous and oral administra-
tion. It has a broad antifungal spectrum and is
active against most Candida and Aspergillus
species. Voriconazole is recommended as first-
line treatment for IA because it had better
clinical outcomes than amphotericin B deoxy-
cholate in an open-label randomized clinical
trial [33].
Renal failure has no relevant influence on
voriconazole PK, but a considerable accumula-
tion of the solvent sulfobutylether-b-cyclodex-
trin (SBECD) was found in patients with renal
failure requiring intravenous administration of
voriconazole. This solvent is a large cyclic
oligosaccharide that is potentially nephrotoxic
at high concentrations. The manufacturer
Table 4 Profile of susceptibility and resistance of Aspergillus species [19]
Fungi
Green, intrinsic susceptibility of the species and first line treatment recommended; red, intrinsic resistance; yellow, sus-
ceptibility to be tested
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recommends oral administration in patients
with a creatinine clearance below 50 mL/min.
Of note, in solid organ transplant patients, the
significant interaction of voriconazole with sir-
olimus contraindicates there concomitant use
[32].
Posaconazole
Posaconazole has a wide antimycotic spectrum,
including activity against Mucorales, and is
licensed for antifungal prophylaxis in selected
hematological high-risk patient. For a decade,
posaconazole was available only as an oral sus-
pension that displayed poor and highly variable
absorption. An intravenous formulation and a
tablet with improved bioavailability are now
available. Posaconazole is a strong inhibitor of
CYP3A4, which is responsible for drug–drug
interactions. In a study that included ICU
patients, the majority had subtherapeutic serum
concentrations during treatment with standard
doses of oral suspension [34]. Mild to moderate
renal or liver impairment had no relevant
influence on posaconazole’s PK.
Isavuconazole
Isavuconazole is a new triazole agent that can
be given once a day and offers a wider spectrum
of antifungal activity than voriconazole,
including activity against most Mucorales. It has
an excellent bioavailability and predictable PK.
It can be used in patients with renal failure
given the absence of cyclodextrin in the intra-
venous formulation. A large double-blind ran-
domized clinical trial showed non-inferiority
for isavuconazole versus voriconazole in terms
of all-cause mortality when used as a primary
treatment for invasive fungal disease caused by
Aspergillus species or other filamentous fungi
[35]. In addition, a matched case–control anal-
ysis of isavuconazole versus amphotericin B
provided evidence for the efficacy and superior
safety profile of isavuconazole in the treatment
of mucormycosis [36]. The most commonly
reported side effects include gastrointestinal
disorders such as nausea, vomiting, and diar-
rhea. A recent double-blind randomized clinical
trial did not show non-inferiority of isavu-
conazole to caspofungin for primary treatment
of IC. Secondary endpoints were similar
between both groups [37].
Gastrointestinal disorders and central ner-
vous adverse effects are possible during isavu-
conazole treatment. Whereas prolongation of
the QT interval is a common adverse effect of
azole antifungals, shortening of the QT interval
has been observed with isavuconazole [38].
Because isavuconazole is a moderate CYP3A4
inhibitor, interactions with immunosuppres-
sants are reported to be less pronounced than
those with voriconazole. However, increased
serum concentrations of cyclosporine A, tacro-
limus, sirolimus, and mycophenolate mofetil
must be anticipated when isavuconazole is co-
administered.
Echinocandins
The echinocandins belong to a class of
semisynthetic lipopeptides that inhibit the
synthesis of the 1,3-beta-D-glucan component
of the fungi cell wall (Fig. 1). Echinocandins
have a broad spectrum of fungicidal activity
against the Candida species, and fungistatic
activity against most Aspergillus species [39]
(Tables 3, 4). Limitations for use of currently
approved echinocandins include the absence of
an oral formulation. Frequently reported side
effects include headache, nausea, diarrhea,
phlebitis, and pruritus. Severe side effects such
as leukopenia, neutropenia, anemia, hypokale-
mia, and liver toxicity are rarely reported
[40–42].
Caspofungin
The standard dose is 70 mg as a single loading
dose followed by a maintenance dose of 50 mg
once a day or 70 mg once a day when body
weight exceeds 80 kg. It displays linear PK.
Immediately after infusion caspofungin under-
goes rapid distribution into tissue, mainly the
liver. About 95% of caspofungin is typically
bound to plasma proteins and it is metabolized
in the liver. For non-ICU patients with moder-
ate hepatic impairment (Child–Pugh score 7–9),
reducing the maintenance dose to 35 mg per
day is recommended [43]. ICU patients with
moderate liver failure may achieve
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subtherapeutic caspofungin exposure with the
adjusted dose of 35 mg per day. The authors
ascribed the low concentrations to typical
physiological alterations occurring in ICU
patients (hypoalbuminemia) [44] and recom-
mended standard doses. Since caspofungin
elimination is largely independent from renal
function, standard doses are suggested in
patients with renal failure, even those with
terminal renal failure requiring hemodialysis
[45–49].
Anidulafungin
Anidulafungin is licensed for the treatment of
IC in adult patients. The recommended dose is
200 mg once a day on day 1 (loading dose) and
then 100 mg daily (maintenance dose). Renal
failure has no influence on anidulafungin
elimination [40]. Unlike caspofungin, liver fail-
ure results in decreased exposure for anidula-
fungin; no dose adjustment is recommended.
An increased degradation due to reduced pro-
tein binding and an enlarged volume of distri-
bution has been suggested [50].
Micafungin
Micafungin was shown to be as effective as both
L-amphotericin B and caspofungin in random-
ized clinical trials [51, 52]. However, the
potential risk for developing liver tumors indi-
cates that use should be restricted to when other
antifungals are not appropriate.
PHARMACOKINETICS FEATURES
ICU Patients
ICU patients, particularly those on broad-spec-
trum antimicrobial treatment, renal replace-
ment therapy, total parenteral nutrition, or
corticosteroid or other immunosuppressive
agents, are at risk of IC. Timely and sufficient
exposure to appropriate antifungals is required
to eradicate fungus. Inadequate initial antifun-
gal doses contribute to both poor outcomes
[53–55] and emergence of resistance [26].
ICU patients have pathophysiological chan-
ges that are responsible for antifungal PK
alterations: organ failure, reduced protein
binding, capillary leakage resulting in an altered
drug volume of distribution, and use of organ
support (i.e., renal replacement therapy and/or
extracorporeal membrane oxygenation,
ECMO). Moreover, interacting co-medications
may result in variable PK of antifungals [56]. In
ICU patients, PK may therefore be very different
from PK of less compromised patients. Appro-
priate dosage of antifungals is challenging
under these special conditions, because respec-
tive PK data are sparse.
The doses determined by data extracted from
other patient groups are suboptimal. Investiga-
tors have attempted to assess the PK variability
of antifungals. A multinational patient study
defining antibiotic levels in the intensive care
unit (DALI) found considerable intervariability
with fluconazole, anidulafungin, and caspo-
fungin, indicating that a large number of
patients do not receive adequate treatment [57].
Those results confirmed previous findings, sug-
gesting the need for routine monitoring of
antifungal serum concentrations [50, 58].
RECOMMENDATIONS OF RECENT
GUIDELINES
IC encompasses three entities: candidemia in
the absence of deep-seated candidiasis, can-
didemia associated with deep-seated candidia-
sis, and deep-seated candidiasis in the absence
of candidemia [59]. The most recent guidelines
for IC management were provided by the
Infectious Diseases Society of America (IDSA) in
2016 and by a task force of the European Society
of Intensive Care Medicine–European Society of
Clinical Microbiology and Infectious Diseases
(ESCMID) in 2019 [29, 60]. The latter specifi-
cally focused on ICU patients (Fig. 2). Both
documents came out against the universal use
of antifungals in patients without clear signs or
symptoms of infections (prophylaxis). However,
guidelines from IDSA posed a weak recommen-
dation (moderate quality evidence) for use of
fluconazole prophylaxis in high-risk patients in
ICUs with IC rates above 5% [29, 60, 61]. Both
documents supported the use of empirical
antifungal treatment (based on signs or
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symptoms of infections without certain proof of
candida infections) only in carefully selected
patients with a high risk of IC, and in con-
junction with other diagnostic tools and data
(e.g., biomarkers such as beta-D-glucan; culture
data from nonsterile sites) [29, 60]. Moreover,
only patients with septic shock, multiple organ
failure, no other causes of fever, and more than
one extradigestive site of Candida spp. colo-
nization (e.g., urine, mouth, throat, upper and
lower respiratory tracts, skin folds, drains,
operative site) should receive empirical anti-
fungal treatment with an echinocandin as the
first-line agent (strong recommendation; low-
quality evidence) [29]. Fluconazole can be used
in less severe patients (no septic shock and/or
multiple organ failure) and in settings with a
low rate of fluconazole resistance. Echinocan-
dins should also be used in patients who are
likely to be infected or colonized by flucona-
zole-resistant Candida spp. (i.e., Candida krusei,
Candida glabrata). This regimen was also rec-
ommended for the targeted treatment of IC
[29, 60].
Transition from echinocandin to fluconazole
(de-escalation) is recommended in clinically
stable patients who have an isolate susceptible
to fluconazole [29] and have negative repeated
blood cultures following the initiation of anti-
fungal treatment [60]. The de-escalation should
not be considered in cases of difficult or
impossible source control (e.g., removing cen-
tral venous catheter, surgery for intra-abdomi-
nal candidiasis). The recommended treatment
duration of candidemia without metastatic
complications is 14 days after the first negative
blood culture [29, 60], taken daily after the
initiation of targeted treatment [60]. In case of
inadequate source control (e.g., no removal of
central venous catheter, no definitive surgical
control or drainage for intra-abdominal can-
didiasis, endocarditis) the duration of therapy
should be individualized [29]. The lipid formu-
lation amphotericin B (3–5 mg per kg per day) is
recommended for infections by azole- and
echinocandin-resistant strains [60]. Of note, a
recent meta-analysis found no evidence of a
therapeutic or survival benefit from choosing
between echinocandins, voriconazole, or
amphotericin B formulations as first-line ther-
apy for ICU adults with invasive infection of the
Candida species [62].
Regarding IA infections in ICU patients, the
2018 ESCMID–European Confederation of
Medical Microbiology–European Respiratory
Society guidelines underlined the difficulty of
diagnosis in ICU patients and suggested that
early diagnosis and treatment of IA should be
based on the integration of clinical findings,
risk factors, radiological data, and
Fig. 2 Practical guidelines for empiric and curative treatment of candidiasis adapted from the IDSA guideline [60]
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microbiological data [63]. A high cutoff (optical
density index 0.5–1) of galactomannan, a pan-
fungal antigen, in the bronchoalveolar lavage
can be considered in decisions regarding when
to start therapy [63]. Thin-section chest com-
puterized tomography is the imaging of choice,
but classic signs are rare in ICU patients, who
usually present non-specific radiological find-
ings [63]. It is still unclear if a prophylactic
treatment may be cost-effective in high-risk
non-neutropenic ICU patients. However, com-
mon risk factors to consider for Aspergillosis in
the ICU are chronic obstructive pulmonary
disease, steroid treatment, sepsis, and influenza-
associated respiratory failure [63]. The first-line
agent is voriconazole (2 9 6 mg per kg on day 1
and then 2 9 4 mg per kg intravenously)
(Table 5). Combination with an echinocandin
can be considered but the quality of the sup-
porting evidence is low. Susceptibility testing is
recommended for voriconazole and therapeutic
drug monitoring in case of treatment failure
[63].
CONCLUSION
Fungi infections are an increasing concern in
ICU patients and have led to the development
of recent guidelines. Three treatment families
are currently used for fungi infections, but
because of the specific pathophysiological status
of ICU patients, PK data on those treatments are
still scarce and numerous questions remain.
Therapeutic drug monitoring is an essential
option for evaluating treatment efficacy and
tolerance.
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